Strides Pharma Science Ltd has announced its consolidated financial results for the fourth quarter and full year ended March 31, 2026, reporting strong growth in profitability and operational performance driven by robust momentum in its Ex-US markets.

For FY26, the company’s U.S. market revenue stood at Rs. 24,897 million ($284 million), registering a 2% year-on-year growth, while Ex-US market revenue rose sharply by 21% YoY to Rs. 22,404 million ($254 million).

Strides reported significant improvement across key financial metrics during the year. Gross margins expanded by 310 basis points year-on-year, while EBITDA margin improved by 140 basis points to 19%.

Operational PAT increased 50.3% year-on-year to Rs. 5,181 million, with Operational EPS rising to Rs. 56.2, reflecting improved operating leverage and profitability.

The company also reported improvement in balance sheet metrics, with Net Debt to EBITDA improving to 1.55x in FY26 compared to 1.9x in FY25. Return on Capital Employed (RoCE) increased to 15.8% from 14.9% in the previous fiscal year.

Reported net debt stood at Rs. 14,365 million, impacted by foreign exchange depreciation amounting to Rs. 1,115 million.

Badree Komandur, MD & Group CEO said, “Strides continued to deliver strong performance across profitability, efficiency, and growth metrics during FY26. This was primarily driven by the Ex-US markets, which recorded a growth of 21% YoY.”